Skip to main content

Polypill Treatment Offers High Value in Low-Income, Underserved Population

Medically reviewed by Carmen Pope, BPharm. Last updated on Jan 13, 2025.

By Elana Gotkine HealthDay Reporter

MONDAY, Jan. 13, 2025 -- Polypill treatment for cardiovascular disease prevention is of high value in a low-income, underserved population, according to a study published online Jan. 8 in JAMA Cardiology.

Ciaran N. Kohli-Lynch, Ph.D., from the Feinberg School of Medicine at Northwestern University in Chicago, and colleagues simulated clinical and economic outcomes of the Southern Community Cohort Study (SCCS) Polypill Trial from a health care sector perspective, adopting a time horizon of 10 years. In the base case analysis, polypill treatment was priced at $463 per year. An SCCS Polypill Trial-representative cohort of 100,000 individuals and all trial-eligible non-Hispanic Black adults were analyzed.

The researchers found that polypill treatment was projected to yield a mean of 1,190 additional quality-adjusted life-years (QALYs) compared with usual care in the trial-representative cohort of 100,000 individuals, at a cost of about $10,152,000. The cost of polypill treatment was estimated at $8,560 per QALY gained compared with usual care, and had high value in 99 percent of simulations. Polypill treatment was estimated to be of high value and cost-saving when priced at $559 or less per year and $443 or less per year, respectively. Polypill treatment remained high value in almost all sensitivity analyses. Polypill treatment offered high value in a secondary analysis of 3,602,427 trial-eligible non-Hispanic Black U.S. adults, with an estimated cost of $13,400 per QALY gained.

"In this economic evaluation, using a computer simulation model, we projected that the polypill would be high value in this population if priced based on its component medications ($463 per year) and may reduce income-related health disparities," the authors write.

One author disclosed ties to Boehringer Ingelheim.

Abstract/Full Text

Editor's Note (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted January 2025

Read this next

Advanced Biological Age Linked to Increased Risk for Incident Dementia

FRIDAY, May 2, 2025 -- Advanced biological age (BA) may be a risk factor for incident dementia, according to a study published online April 30 in Neurology. Yacong Bo, Ph.D...

Urinary Incontinence Linked to CVD Risk Factors, Comorbid Conditions

FRIDAY, May 2, 2025 -- Urinary incontinence is not associated with moderate-to-vigorous physical activity (MVPA) classification, but is associated with cardiovascular disease...

Exposure to Smoke Pollution Ups Risk for Hospitalization for Respiratory Disease

FRIDAY, May 2, 2025 -- For older adults in the Western United States, exposure to high levels of smoke pollution is associated with an increase in hospitalizations for respiratory...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.